Navigation Links
FDA Advisory Committee Unanimously Recommends Approval of Ustekinumab for Treatment of Moderate to Severe Plaque Psoriasis
Date:6/17/2008

and ophthalmologic conditions. The committee provides non-binding recommendations based on its evaluation; however, final decisions on approval of the drug are made by the FDA.

About Psoriasis

Psoriasis is a chronic, immune-mediated disease, caused by the overproduction of skin cells, resulting in their accumulation on the surface of the skin, which causes red, scaly plaques that may itch and bleed. It is estimated that 125 million people worldwide have psoriasis, including two percent of both the U.S. and European populations, or some 7.5 million Americans and 10 million Europeans. Nearly one-quarter of people with psoriasis have cases that are considered moderate to severe.

About Ustekinumab

Ustekinumab is a new, human monoclonal antibody in Phase 3 development by Centocor, Inc. for the treatment of moderate to severe plaque psoriasis, and is being investigated as an infrequently administered subcutaneous injection. Ustekinumab is a novel biologic therapy that targets interleukin 12 (IL-12) and interleukin 23 (IL-23), naturally occurring proteins that are important in regulating the immune system and that are also believed to play a role in psoriasis.

Centocor discovered ustekinumab and has exclusive marketing rights to the product in the United States. Janssen-Cilag companies have exclusive marketing rights in all countries outside of the United States.

About Centocor, Inc.

Centocor is harnessing the power of world-leading research and biomanufacturing to deliver innovative biomedicines that transform patients' lives. Centocor has already brought innovation to the treatment of Crohn's disease, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, ulcerative colitis, pediatric Crohn's disease and psoriasis.

The world leader in monoclonal antibody production and technology, Centocor has brought critical biologic therapies to patients suffering from debilitating immune disorders. Centocor is a whol
'/>"/>

SOURCE Centocor, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. UBC Forms European Advisory Board to Enhance Data Quality of CNS Trials
2. Ortho Biotech Statement on U.S. Food and Drug Administration Oncologic Drugs Advisory Committee Vote
3. FDA Advisory Committee Unanimously Recommends U.S. Approval of Sugammadex, the First and Only Selective Relaxant Binding Agent
4. HUYA Bioscience Intl Announces World-Class Clinical Advisory Team for New Anti-Arrhythmic Compound Sourced From China
5. FDA Advisory Committee Supports Efficacy and Safety of Zyprexa(R) Long-Acting Injection (LAI) for Schizophrenia Treatment
6. Solvay Pharmaceuticals, Inc. Responds to Advisory Committee Recommendation for Further Study of Tedisamil to Treat Atrial Fibrillation
7. Schiffrin Barroway Topaz & Kessler, LLP and Janet Jenner & Suggs, LLC Comment on Conagra Advisory Regarding Pot Pies Linked to Salmonella Outbreak
8. Targeted Genetics Reports on Recombinant DNA Advisory Committee (RAC) Review of its Phase 1/2 Trial of tgAAC94 for Rheumatoid Arthritis
9. Statement by KCP Chairman Dr. Edward Jones in Response to FDA Advisory Committee on Benefits and Risks of Erythropoietin-Stimulating Agents in Treatment of Kidney Patients
10. FDA Advisory Committees Recommend Continued U.S. Marketing Authorization for Trasylol(R)
11. IDM Pharma Announces Non-Binding Opinion of the European Committee for Medicinal Products for Human Use (CHMP) that Mifamurtide (L-MTP-PE) Provides a Possible Clinical Benefit in Survival
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... -- Stryker brand ambassadors Fred Funk and Hal ... Tour event near Minneapolis, MN , which begins ... Stryker is the official joint replacement products company of the PGA ... st through Sunday, August 3 rd , fans will be ... destination located in the Pioneer Press Expo tent located near the ...
(Date:7/30/2014)... PARIS , July 30, 2014  Regeneron ... (EURONEXT: SAN and NYSE: SNY ) today ... alirocumab in people with hypercholesterolemia met their primary efficacy ... low-density lipoprotein cholesterol (LDL-C) at 24 weeks compared to ... antibody targeting PCSK9 (proprotein convertase subtilisin/kexin type 9). ...
(Date:7/30/2014)... and SAN DIEGO , July ... ARNA ) announced today that an article based ... of lorcaserin entitled, "Early Weight Loss While on Lorcaserin, Diet, ... was recently published in the online issue of Obesity ... The objective of these analyses was to identify whether there ...
Breaking Medicine Technology:Stryker Brand Ambassadors Fred Funk And Hal Sutton Set To Play At 3M Championship 2Stryker Brand Ambassadors Fred Funk And Hal Sutton Set To Play At 3M Championship 3Stryker Brand Ambassadors Fred Funk And Hal Sutton Set To Play At 3M Championship 4Stryker Brand Ambassadors Fred Funk And Hal Sutton Set To Play At 3M Championship 5Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 2Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 3Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 4Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 5Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 6Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 7Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 8Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 2Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 3Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 4Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 5Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 6Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 7
... Mylan Inc. (Nasdaq: MYL ) today announced that it has ... amount of 7.625% Senior Notes due 2017 and $700 million ... is using $1.0 billion of the net proceeds from ... loans, thereby reducing senior secured leverage and extending the maturity profile ...
... SHENZHEN, China , May 19 /PRNewswire-Asia/ ... Medical" or the "Company"), a leading manufacturer of,medical dressings, ... consumer products industries, announced today that in,connection with the ... common stock, par value $0.001 per share, ...
Cached Medicine Technology:Mylan Announces Completion of Senior Notes Offering 2Winner Medical Group Inc. Announces Exercise of Over-Allotment Option Bringing Aggregate Net Proceeds of the Public Offering to $8.8 Million 2Winner Medical Group Inc. Announces Exercise of Over-Allotment Option Bringing Aggregate Net Proceeds of the Public Offering to $8.8 Million 3Winner Medical Group Inc. Announces Exercise of Over-Allotment Option Bringing Aggregate Net Proceeds of the Public Offering to $8.8 Million 4
(Date:7/30/2014)... July 30, 2014 Hospitals continually ... quality of care that their practitioners provide. During ... Andrew Rowe, discussed the importance of establishing effective ... physician performance and quality of care. , ... evaluation, Mr. Rowe elaborated on setting performance expectations, ...
(Date:7/30/2014)... Frozen shoulder (Adhesive capsulitis) affects 10-20 percent ... this nasty condition which occurs most frequently in people between ... to two and half years if not treated. , Adhesive ... good reason: it can render your shoulder so stiff, it's ... you aren't in too much pain to get dressed in ...
(Date:7/30/2014)... (HealthDay News) --,Although the vast majority of kids with ... wired very differently from children who have trouble processing ... disorders (SPD) can be overly sensitive to sound, sight ... and show a lack of concentration. Complicating matters, ... others. Some have trouble tolerating loud noises, like a ...
(Date:7/30/2014)... India (PRWEB) July 30, 2014 On ... Campaign, and the Indian Institute of Public Health, Gandhinagar ... Microfinance in India, Volume II: The Way Forward .” ... Asia Conference on Policies and Practices to Improve Nutrition ... the "Indian Father of the Green Revolution" and chair ...
(Date:7/30/2014)... 2014 The North America aviation actuator ... 2019. North America is expected to be the fastest ... a CAGR of 5.60%. , The commercial aircraft ... which will assume prominence in the years to come. ... the sector has regained quickly, and the industry has ...
Breaking Medicine News(10 mins):Health News:AllMed Webinar Helps Hospitals Optimize Practitioner Evaluations in Peer Review 2Health News:AllMed Webinar Helps Hospitals Optimize Practitioner Evaluations in Peer Review 3Health News:Good News for Diabetics Suffering from Frozen Shoulder 2Health News:Good News for Diabetics Suffering from Frozen Shoulder 3Health News:Good News for Diabetics Suffering from Frozen Shoulder 4Health News:Different Areas of Brain Affected in Autism, Sensory Disorders 2Health News:Different Areas of Brain Affected in Autism, Sensory Disorders 3Health News:New Report on Integrated Health and Microfinance in India Shows the Way Forward 2Health News:New Report on Integrated Health and Microfinance in India Shows the Way Forward 3Health News:New Report on Integrated Health and Microfinance in India Shows the Way Forward 4Health News:North America Aviation Actuation System Market is Expected to Reach $1781.02 million in 2019 - New Report by MicroMarket Monitor 2Health News:North America Aviation Actuation System Market is Expected to Reach $1781.02 million in 2019 - New Report by MicroMarket Monitor 3Health News:North America Aviation Actuation System Market is Expected to Reach $1781.02 million in 2019 - New Report by MicroMarket Monitor 4
... of the effects of regulation on small businesses ... entrepreneurship, according to a new RAND Corporation report. ... Policy report provides an overview of the ways ... or encourage the entrepreneurial spirit. It also ...
... Biodel Inc. (Nasdaq:,BIOD) today reported fourth quarter and ... pipeline progress and disclosed 2008,objectives., "In 2007, ... advanced our pipeline,and achieved critical corporate objectives," stated ... significant milestones reached include our,successful initial public offering, ...
... Calif., Dec. 11 Varian Medical,Systems (NYSE: VAR ... the company,s Annual Meeting of Stockholders for February 14,2008 ... meeting will be held at,the Sheraton Palo Alto, 625 ... The meeting will be webcast by CCBN and ...
... such as lumps, the ability of diagnostic mammograms to ... reads them, according to a Group Health study published ... National Cancer Institute., When a woman gets a mammogram, ... cancer, the mammogram will be likely to detect it, ...
... Simple bystander-delivered CPR without mouth-to-mouth boosted survival outcomes ... compressions alone (without mouth-to-mouth resuscitation) may be as ... mouth-to-mouth) when bystanders come to the aid of ... conclusion of two studies published in the Dec. ...
... be needed, experts say , , TUESDAY, Dec. 11 (HealthDay ... care for low-income seniors produced mixed results, a geriatrics ... the need for a new analysis of how Medicare ... , "We were able to stabilize medical care for ...
Cached Medicine News:Health News:Rand study examines the effect of policy on entrepreneurship and small businesses 2Health News:Biodel Inc. Reports Fourth Quarter and Fiscal Year 2007 Financial Results 2Health News:Biodel Inc. Reports Fourth Quarter and Fiscal Year 2007 Financial Results 3Health News:Biodel Inc. Reports Fourth Quarter and Fiscal Year 2007 Financial Results 4Health News:Biodel Inc. Reports Fourth Quarter and Fiscal Year 2007 Financial Results 5Health News:Biodel Inc. Reports Fourth Quarter and Fiscal Year 2007 Financial Results 6Health News:Biodel Inc. Reports Fourth Quarter and Fiscal Year 2007 Financial Results 7Health News:Biodel Inc. Reports Fourth Quarter and Fiscal Year 2007 Financial Results 8Health News:Biodel Inc. Reports Fourth Quarter and Fiscal Year 2007 Financial Results 9Health News:Varian Medical Systems Schedules Annual Stockholder Meeting in Palo Alto 2Health News:Accuracy of diagnostic mammograms varies by radiologist 2Health News:Chest Compressions Effective in Emergency Cardiac Arrest 2Health News:Home-Based Senior Care Program Has Limited Benefits 2
... Bird and Cronin, Inc. ... of Patient Footwear, Orthopedic ... Care Products. Our products ... quality and available in ...
... Spica Splint provides effective long-term stabilization ... fit. Adjustable radial and palmar stays ... Gamekeper's thumb, de Quervain's, scaphoid and ... straps.,FormFit™ Splints offer superior fit and ...
Qualcare™ Thumb Spica...
... QuickCast® Cast-like splints Slip ... dryer, and QuickCast conforms to ... cools. Reheat to adjust and ... coated with a temperature-sensitive polymer ...
Medicine Products: